文献速递脑血管病

急性缺血性卒中后组织金属蛋白酶抑制因子-1与临床结局

Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke.
PubMed 文献 · Neurology · 2019-09-24

本研究基于中国急性缺血性卒中降压试验,测量3342例患者基线血清TIMP-1浓度,发现较高TIMP-1水平与3个月死亡和主要残疾风险增加相关,且能改善风险预测。

要点

  • 较高血清TIMP-1与急性缺血性卒中后3个月死亡和主要残疾风险增加独立相关。
  • TIMP-1加入常规风险因素模型可改善主要结局的风险预测。
  • TIMP-1与MMP-9同时升高者所有研究结局风险最高。

核心结论

  • 较高TIMP-1水平与急性缺血性卒中后死亡和主要残疾风险增加相关。

研究设计与样本

  • 研究数据来自中国急性缺血性卒中降压试验,测量了3342名参与者的基线血清TIMP-1浓度。

主要发现

  • 843名参与者(25.2%)在3个月内发生主要残疾或死亡。
  • 调整年龄、性别、入院NIHSS评分及其他重要协变量后,log-TIMP-1每升高1-SD(0.17 ng/mL),主要结局OR为1.17(95%CI 1.06-1.29),主要残疾OR为1.13(95%CI 1.02-1.25),死亡HR为1.49(95%CI 1.19-1.87),死亡和血管事件复合结局HR为1.34(95%CI 1.11-1.62)。
  • 将血清TIMP-1加入常规风险因素模型显著改善主要结局的风险预测(净重分类指数9.0%,p=0.02;综合判别改善0.2%,p=0.03)。
  • TIMP-1和MMP-9同时较高的参与者所有研究结局风险最高。

临床怎么用

  • 血清TIMP-1可作为急性缺血性卒中后预后评估的潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To prospectively investigate the relationships between serum tissue inhibitor metalloproteinase-1 (TIMP-1) and clinical outcomes in patients with acute ischemic stroke. METHODS: We derived data from the China Antihypertensive Trial in Acute Ischemic Stroke. Baseline serum TIMP-1 concentrations were measured in 3,342 participants. The primary outcome was the combination of death and major disability (modified Rankin Scale score ≥3) at 3 months after ischemic stroke, and secondary outcomes included major disability, death, and vascular events. RESULTS: A total of 843 participants (25.2%) experienced major disability or died within 3 months. After adjustment for age, sex, admission NIH Stroke Scale score, and other important covariates, odds ratios or hazard ratios (95% confidence intervals) of 1-SD (0.17 ng/mL) higher log-TIMP-1 were 1.17 (1.06-1.29) for the primary outcome, 1.13 (1.02-1.25) for major disability, 1.49 (1.19-1.87) for death, and 1.34 (1.11-1.62) for the composite outcome of death and vascular events. The addition of serum TIMP-1 to conventional risk factors model significantly improved risk prediction of the primary outcome (net reclassification index 9.0%, p = 0.02; integrated discrimination improvement 0.2%, p = 0.03). Participants with both higher TIMP-1 and matrix metalloproteinase-9 levels simultaneously had the highest risk of all study outcomes. CONCLUSIONS: Higher TIMP-1 levels were associated with increased risk of mortality and major disability after acute ischemic stroke. Our findings provided evidence supporting the important prognostic role of extracellular matrix biomarkers after acute ischemic stroke.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zhong C, Wang G, Xu T, et al. Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke. Neurology. 2019. PMID: 31551260. doi:10.1212/WNL.0000000000008389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。